Martin Wermke

16PUBLICATIONS
107CO-AUTHORS
Tumour immunologyGene and molecular therapyLiquid biopsiesCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

|Sep 27, 2025
First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms.

Simone Thomas, Martin Wermke, Vladan Vučinić

|Sep 04, 2025
Histologic Transformation in Cancer: The Path for Clinical Translation.

Ioannis Vathiotis, Avisek Banerjee, Utsav Sen

|Jul 24, 2025
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.

Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki

|Jun 02, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.

Theresa Medina, Jason A Chesney, Harriet M Kluger

|Apr 09, 2025
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.

Martin Wermke, Dejka M Araujo, Manik Chatterjee

Pageof 3

Frequent Collaborators

4 joint publications

Cedrik Michael Britten

4 joint publications

Norbert Hilf

2 joint publications

Yael C Cohen

2 joint publications

Kristin Henson